

# Jason Tay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5253063/publications.pdf>

Version: 2024-02-01

89  
papers

2,045  
citations

257450

24  
h-index

265206

42  
g-index

91  
all docs

91  
docs citations

91  
times ranked

3603  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                     | IF  | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1  | A Systematic Review of Preclinical Studies on the Therapeutic Potential of Mesenchymal Stromal Cell-Derived Microvesicles. <i>Stem Cell Reviews and Reports</i> , 2015, 11, 150-160.                                                                        | 5.6 | 248       |
| 2  | Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 653-663.                  | 3.8 | 164       |
| 3  | Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 206-217. | 2.0 | 111       |
| 4  | Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.                                                                                                                       | 2.0 | 98        |
| 5  | Incidence and predictive factors of symptomatic thrombosis related to peripherally inserted central catheters in chemotherapy patients. <i>Thrombosis Research</i> , 2012, 130, 323-326.                                                                    | 1.7 | 89        |
| 6  | Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016, 127, 3082-3091.                                                                                                            | 1.4 | 83        |
| 7  | Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.                                                                                               | 2.0 | 73        |
| 8  | Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. <i>JAMA Neurology</i> , 2016, 73, 652.                                                                                                                                   | 9.0 | 71        |
| 9  | Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1191-1203.                 | 2.0 | 69        |
| 10 | Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. <i>Leukemia</i> , 2018, 32, 986-995.                                                           | 7.2 | 60        |
| 11 | Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1039-1044.               | 2.0 | 53        |
| 12 | The Influence of Social Support on Hematopoietic Stem Cell Transplantation Survival: A Systematic Review of Literature. <i>PLoS ONE</i> , 2013, 8, e61586.                                                                                                  | 2.5 | 43        |
| 13 | Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation: Practical Approach to Imaging Diagnosis. <i>Radiographics</i> , 2014, 34, 663-683.                                                                                     | 3.3 | 42        |
| 14 | Is Cytomegalovirus Testing of Blood Products Still Needed for Hematopoietic Stem Cell Transplant Recipients in the Era of Universal Leukoreduction?. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1719-1724.                              | 2.0 | 39        |
| 15 | Transplantation of Umbilical Cord Blood-Derived Cells for Novel Indications in Regenerative Therapy or Immune Modulation: A Scoping Review of Clinical Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 20-25.                       | 2.0 | 38        |
| 16 | Revised International Staging System Applied to Real World Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 511-518.                                                                                                   | 0.4 | 37        |
| 17 | Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2552-2554.                                                    | 3.8 | 35        |
| 18 | Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1513-1518.                                                      | 2.4 | 34        |

| #  | ARTICLE                                                                                                                                                                                                                       | IF  | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Post-Transplant Outcomes in High-Risk Compared with Nonâ€“High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.                                            | 2.0 | 34        |
| 20 | New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.                                                                                          | 2.0 | 33        |
| 21 | Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1463-1473. | 1.6 | 32        |
| 22 | Autologous Stem Cell Transplantation for Stiff Person Syndrome. <i>JAMA Neurology</i> , 2014, 71, 1296.                                                                                                                       | 9.0 | 29        |
| 23 | Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial. <i>Trials</i> , 2011, 12, 207.                                                                 | 1.6 | 25        |
| 24 | Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 431-439.                                                                          | 1.8 | 25        |
| 25 | Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds. <i>Blood</i> , 2016, 128, 1032-1032.                           | 1.4 | 22        |
| 26 | Acquired Factor XIII Inhibitor in Hospitalized and Perioperative Patients: A Systematic Review of Case Reports and Case Series. <i>Transfusion Medicine Reviews</i> , 2016, 30, 123-131.                                      | 2.0 | 21        |
| 27 | The Impact of Prolonged Storage of Red Blood Cells on Cancer Survival. <i>PLoS ONE</i> , 2013, 8, e68820.                                                                                                                     | 2.5 | 18        |
| 28 | High incidence of <i>Pneumocystis jirovecii</i> pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era. <i>Cytotherapy</i> , 2020, 22, 27-34.                                                     | 0.7 | 18        |
| 29 | Storage time of transfused red blood cells and impact on clinical outcomes in hematopoietic stem cell transplantation. <i>Transfusion</i> , 2011, 51, 2488-2494.                                                              | 1.6 | 17        |
| 30 | A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program. <i>Bone Marrow Transplantation</i> , 2014, 49, 751-755.                  | 2.4 | 17        |
| 31 | Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and metaâ€“analysis. <i>Transfusion</i> , 2018, 58, 2437-2452.                 | 1.6 | 17        |
| 32 | Impact of ethnicity on human umbilical cord blood banking: a systematic review. <i>Transfusion</i> , 2014, 54, 2122-2127.                                                                                                     | 1.6 | 15        |
| 33 | Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. <i>Blood</i> , 2014, 124, 38-38.    | 1.4 | 15        |
| 34 | Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation. <i>Transfusion</i> , 2015, 55, 253-258.                                                                         | 1.6 | 14        |
| 35 | Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and metaâ€“analysis â€“ Part II: Nonâ€“kidney transplant. <i>Clinical Transplantation</i> , 2019, 33, e13625.    | 1.6 | 14        |
| 36 | Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?. <i>Bone Marrow Transplantation</i> , 2017, 52, 915-917.                                                         | 2.4 | 13        |

| #  | ARTICLE                                                                                                                                                                                                                                                          | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. <i>Leukemia and Lymphoma</i> , 2018, 59, 1920-1926.                                                                      | 1.3 | 13        |
| 38 | Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561. | 2.0 | 13        |
| 39 | Immune Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients. <i>Blood</i> , 2018, 132, 242-242.                            | 1.4 | 13        |
| 40 | Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation. <i>BMJ Open</i> , 2015, 5, e008316.                            | 1.9 | 12        |
| 41 | Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation. <i>Transfusion</i> , 2008, 48, 2421-2428. | 1.6 | 11        |
| 42 | Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables. <i>Bone Marrow Transplantation</i> , 2019, 54, 368-382.                                                                                               | 2.4 | 11        |
| 43 | Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2019, 33, e13560.                                                                              | 1.6 | 11        |
| 44 | Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 394-399.                                        | 0.4 | 11        |
| 45 | Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials. <i>Transfusion</i> , 2016, 56, 2607-2614.                                                          | 1.6 | 10        |
| 46 | Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation. <i>Transfusion</i> , 2012, 52, 2049-2054.                                                                                                     | 1.6 | 9         |
| 47 | Major ABO-incompatible BMT: isohemagglutinin reduction with plasma exchange is safe and avoids graft manipulation. <i>Bone Marrow Transplantation</i> , 2013, 48, 953-957.                                                                                       | 2.4 | 9         |
| 48 | Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2712-2720.                                                               | 1.3 | 9         |
| 49 | A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers. <i>Transplant Infectious Disease</i> , 2017, 19, e12706.                                                                                             | 1.7 | 9         |
| 50 | Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center. <i>Leukemia and Lymphoma</i> , 2019, 60, 3199-3203.                                                                                             | 1.3 | 9         |
| 51 | Clinical outcomes of immunoglobulin use in solid organ transplant recipients: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2015, 4, 167.                                                                                      | 5.3 | 8         |
| 52 | Rh D alloimmunization in allogeneic HSCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 459-460.                                                                                                                                                                | 2.4 | 7         |
| 53 | Balancing give and take between patients and their spousal caregivers in hematopoietic stem cell transplantation. <i>Psycho-Oncology</i> , 2017, 26, 2224-2231.                                                                                                  | 2.3 | 7         |
| 54 | Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. <i>Leukemia and Lymphoma</i> , 2019, 60, 1275-1282.             | 1.3 | 7         |

| #  | ARTICLE                                                                                                                                                                                                                                                                           | IF  | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Retrospective Review of Invasive Fungal Disease in a Cohort of Patients with Acute Leukemia. <i>Blood</i> , 2011, 118, 4265-4265.                                                                                                                                                 | 1.4 | 7         |
| 56 | A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 135-140.                                                                            | 1.3 | 6         |
| 57 | Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study. <i>BMJ Open</i> , 2016, 6, e013483.                                                                                                                              | 1.9 | 6         |
| 58 | Improved Prediction of CD34 + Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Valueâ€œTailored Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 763-767.                                              | 2.0 | 6         |
| 59 | Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e69-e75.                                                                                       | 0.4 | 6         |
| 60 | The Use of Intravenous Antibiotics at the Onset of Neutropenia in Patients Receiving Outpatient-Based Hematopoietic Stem Cell Transplants. <i>PLoS ONE</i> , 2012, 7, e46220.                                                                                                     | 2.5 | 6         |
| 61 | Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019007.                                                                                                 | 1.3 | 5         |
| 62 | The impact of COVIDâ€œ19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A singleâ€œcenter experience. <i>European Journal of Haematology</i> , 2021, 106, 340-345.                                                                                    | 2.2 | 5         |
| 63 | Donor selection for patients undergoing allogeneic hematopoietic SCT: assessment of the priorities of Canadian hematopoietic SCT physicians. <i>Bone Marrow Transplantation</i> , 2013, 48, 314-316.                                                                              | 2.4 | 4         |
| 64 | Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 182-188.  | 3.0 | 4         |
| 65 | Economics of Multiple Myeloma. <i>Blood</i> , 2018, 132, 4773-4773.                                                                                                                                                                                                               | 1.4 | 4         |
| 66 | Observational studies: what is a cohort study?. <i>Transfusion</i> , 2007, 47, 1115-1117.                                                                                                                                                                                         | 1.6 | 3         |
| 67 | Current Trends in Clinical Studies of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 364-370.                                                                                                                 | 2.0 | 3         |
| 68 | Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers. <i>Blood Cancer Journal</i> , 2018, 8, 14.                                                                                 | 6.2 | 3         |
| 69 | Cutaneous plasmacytoma-like posttransplant lymphoproliferative disorder after renal transplantation with response to imiquimod 5% cream and reduced immunosuppression. <i>JAAD Case Reports</i> , 2019, 5, 1071-1074.                                                             | 0.8 | 3         |
| 70 | N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution. <i>Annals of Hematology</i> , 2021, 100, 2521-2527.                                                                                          | 1.8 | 3         |
| 71 | Outcomes of both abbreviated hyperâ€œCVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10â€œyear singleâ€œcentre experience with literature review. <i>Cancer Medicine</i> , 2015, 4, 1817-1827. | 2.8 | 2         |
| 72 | Antiâ€œmyeloma potential of ruxolitinib in coâ€œexisting JAK2V617F â€œpositive smouldering myeloma and polycythaemia vera. <i>British Journal of Haematology</i> , 2020, 189, e114-e118.                                                                                          | 2.5 | 2         |

| #  | ARTICLE                                                                                                                                                                                                                                                                                                                                                                                                                                                          | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Cyclophosphamide, Bortezomib and Methylprednisolone (CyBORMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 675-678.                                                                                                                                                                                                                                               | 0.6 | 2         |
| 74 | Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing. Blood, 2018, 132, 4459-4459.                                                                                                                                                                                                                                                                                                       | 1.4 | 2         |
| 75 | Thromboprophylaxis In Multiple Myeloma Patients Undergoing Immunomodulatory Therapy with Thalidomide and Lenalidomide: A Systematic Review and Meta-Analysis.. Blood, 2010, 116, 1090-1090.                                                                                                                                                                                                                                                                      | 1.4 | 2         |
| 76 | Serial assessment of toxicity after hematopoietic SCT can discern kinetics of transplant-related organ injury and patterns of recovery. Bone Marrow Transplantation, 2012, 47, 1375-1376.                                                                                                                                                                                                                                                                        | 2.4 | 1         |
| 77 | A Canadian Cost Analysis Comparing the Use of Bortezomib or Lenalidomide as Maintenance Therapies in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant. Value in Health, 2014, 17, A77.                                                                                                                                                                                                                                                     | 0.3 | 1         |
| 78 | Red cell transfusion thresholds in haematopoietic stem cell transplantation. ISBT Science Series, 2019, 14, 123-128.                                                                                                                                                                                                                                                                                                                                             | 1.1 | 1         |
| 79 | The Impact of Marital Status on Hematopoietic Stem Cell Transplant (HCT) Recipient Outcomes: A Surrogate for Consistent Caregiver. a CIBMTR Registry Study. Blood, 2018, 132, 4788-4788.                                                                                                                                                                                                                                                                         | 1.4 | 1         |
| 80 | Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada. Leukemia and Lymphoma, 0, , 1-8.                                                                                                                                                                                                                                                                                                                            | 1.3 | 1         |
| 81 | Network geometry of evidence from randomised controlled trials addressing donor selection and source of haematopoietic progenitor cells used in allogeneic transplantation: a systematic scoping review. Transfusion Medicine, 2018, 28, 371-379.                                                                                                                                                                                                                | 1.1 | 0         |
| 82 | Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies,. Blood, 2011, 118, 4046-4046.                                                                                                                                                                                                                                                                  | 1.4 | 0         |
| 83 | The Influence of the Duration of Storage of Red Blood Cells On Cancer Survival. Blood, 2012, 120, 1184-1184.                                                                                                                                                                                                                                                                                                                                                     | 1.4 | 0         |
| 84 | First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity. Blood, 2014, 124, 3990-3990.                                                                                                                     | 1.4 | 0         |
| 85 | Identification and Management of Glucocorticoid-Induced Hyperglycemia on an Inpatient Malignant Hematology Ward: A Quality Improvement Initiative. Blood, 2014, 124, 6004-6004.                                                                                                                                                                                                                                                                                  | 1.4 | 0         |
| 86 | Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Hevylite™, chain (HLC) Normalization. Blood, 2015, 126, 1982-1982. | 1.4 | 0         |
| 87 | Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns. Blood, 2018, 132, 4496-4496.                                                                                                                                                                                                                                                                                                                                 | 1.4 | 0         |
| 88 | Monoclonal Gammopathy of Clinical Significance - a Single Center Experience. Blood, 2018, 132, 4495-4495.                                                                                                                                                                                                                                                                                                                                                        | 1.4 | 0         |
| 89 | Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, , 1-2.                                                                                                                                                                                     | 3.0 | 0         |